Repurposing Approved Drugs to Modulate DNA Repair in CRISPR Editing

Study Background and Research Question

DNA double-strand breaks (DSBs) are critical lesions that can arise spontaneously or be induced by exogenous sources, such as ionizing radiation or genome editing nucleases like CRISPR-Cas9. The cell must repair these breaks to maintain genomic integrity, predominantly through non-homologous end joining (NHEJ) or microhomology-mediated end joining (MMEJ), with homology-directed repair (HDR) providing a less frequent but more precise alternative. The relative activity of these pathways influences the outcomes of genome editing and cancer therapy. However, the ability to pharmacologically steer repair pathway choice remains limited. The study by Macak, Kanis, and Riesenberg addresses whether clinically approved drugs can be repurposed to modulate DSB repair pathway usage, thereby improving precision in gene editing and creating new avenues for synthetic lethality in cancer cells (paper).

Key Innovation from the Reference Study

The primary innovation is a high-throughput screen of more than 7,000 FDA-approved drugs in human induced pluripotent stem cells (hiPSCs) engineered with a doxycycline-inducible Cas9 system. This approach allows for systematic identification of compounds that enhance or inhibit specific DSB repair pathways—NHEJ, MMEJ, or HDR—during genome editing. The screen directly quantifies how each drug alters the spectrum of mutational outcomes after CRISPR-induced breaks, enabling both pathway-specific modulation and discovery of drugs with synthetic lethality effects when particular pathways are blocked (paper).

Methods and Experimental Design Insights

The researchers employed 409B2 hiPSCs expressing inducible Cas9 (iCRISPR) to target the FRMD7 locus. After drug treatment and induction of DSBs, cells were allowed to recover, and survival was measured using resazurin fluorescence. Genomic DNA was then extracted, and Illumina sequencing was performed to categorize repair outcomes: precise edits (HDR), indels with minimal microhomology (NHEJ), and deletions consistent with MMEJ activity. This allowed precise assignment of each drug's effect on pathway choice and editing efficiency. For functional validation, select genes such as ESR2 and AOX1 were silenced to examine synergistic interactions with pharmacological inhibition, notably demonstrating increased HDR frequencies when ESR2 knockdown was combined with NHEJ inhibitors (paper).

Protocol Parameters

• iCRISPR hiPSC editing | 10 µM drug treatment (typical screening dose) | DSB repair pathway modulation | Standardized dose enables direct comparison across >7,000 compounds | paper
• Cell survival assay | Resazurin fluorescence, endpoint measurement | Synthetic lethality assessment | Quantifies cell viability under repair pathway disruption | paper
• Sequencing of repair outcomes | Illumina, deep coverage | Pathway assignment (NHEJ, MMEJ, HDR) | Accurate quantification of editing spectra | paper
• Dantrolene sodium salt as RyR antagonist | 5.9 ± 0.3 nM IC50 for RyR2 | Calcium signaling modulation in genome editing | Nanomolar potency validated in cardiomyocytes | product_spec
• Dantrolene sodium salt storage | Room temperature (solid); DMSO solution for short-term use | Assay reproducibility | Ensures chemical stability for experimental workflows | product_spec

Core Findings and Why They Matter

The large-scale drug screen identified multiple clinically approved compounds capable of shifting DSB repair pathway usage. Some drugs enhanced HDR frequency, increasing the precision of template-guided genome editing, while others selectively inhibited NHEJ or MMEJ, enabling improved control over indel formation. For example, inhibition of NHEJ or MMEJ increased rates of HDR or alternative end joining, depending on the genetic and pharmacologic context. Notably, silencing ESR2 in combination with NHEJ inhibition synergistically amplified HDR frequency by a mean of 4.6-fold (paper), highlighting combinatorial strategies for pathway control. Furthermore, the study uncovered drugs that induce synthetic lethality when repair is restricted, suggesting new options for cancer therapy tailored to specific repair deficiencies. These results have broad implications for gene therapy, disease modeling, and immuno-oncology, where repair pathway choice determines both efficacy and safety of genome editing interventions.

Comparison with Existing Internal Articles

Several internal resources offer practical perspectives on modulating DNA repair and calcium signaling in genome editing workflows. For example, the article "Dantrolene Sodium Salt: RyR Antagonist for Calcium Homeos..." highlights dantrolene sodium salt as a benchmark ryanodine receptor antagonist that enables experimental control over intracellular calcium release, a process closely linked to DSB repair efficiency and pathway selection (source: workflow_recommendation). Another guide, "Advanced Ryanodine Receptor Antagonist Workflows", provides detailed protocol suggestions for integrating dantrolene in calcium signaling and genome editing experiments. These resources align with the reference study's emphasis on pharmacological modulation, supporting the use of compounds like dantrolene sodium salt for precision control in CRISPR workflows and synthetic lethality assays.

Limitations and Transferability

While the high-throughput approach yields valuable insights, several limitations warrant consideration. The screen was performed in a specific hiPSC line and at a fixed drug concentration, which may not capture context-dependent effects in other cell types or under physiological dosing. Single-replicate screening introduces potential for false positives or negatives, although follow-up validation was performed for key hits. Furthermore, while the study identifies drugs with pathway-modulating activity, mechanistic details for many compounds remain to be established. Transferability to in vivo gene therapy or diverse disease models will require additional validation and dose optimization. Finally, the interplay between calcium signaling, RyR antagonism, and DNA repair pathway choice is an emerging area that would benefit from further mechanistic dissection (source: workflow_recommendation).

Why this cross-domain matters, maturity, and limitations

The study bridges drug repurposing, genome editing technology, and precision medicine: compounds traditionally used in unrelated indications can be harnessed to steer DNA repair outcomes in gene therapy or cancer models. However, direct translation to clinical genome editing protocols will depend on rigorous mechanistic and safety validation. The mechanistic overlap between calcium signaling modulation—via ryanodine receptor antagonists such as dantrolene sodium salt—and DNA damage response regulation presents a promising but still maturing field. Researchers should be cautious in extrapolating high-throughput screening results to complex in vivo contexts, where systemic effects and off-target activities can modulate outcomes.

Research Support Resources

To facilitate experimental workflows in calcium signaling and DNA repair modulation, researchers can utilize Dantrolene, sodium salt (SKU B6329), a potent and selective ryanodine receptor antagonist with validated nanomolar potency and calmodulin-dependent inhibition (source: product_spec). This compound is supplied by APExBIO with high purity and full QC documentation, supporting its use in genome editing, neurodegenerative disease models, and studies of ischemia, hypoxia, or pancreatitis (source: product_spec). For detailed protocol suggestions and troubleshooting strategies, internal resources such as "Precision Ryanodine Receptor Antagonist Workflows" (link) and "Dantrolene Sodium Salt: Advanced Workflows" (link) offer actionable guidance for integrating dantrolene sodium salt into advanced CRISPR and synthetic lethality research.